z-logo
open-access-imgOpen Access
The role of adiponectin and its receptor in patients with idiopathic membranous nephropathy complicated with hyperuricemia
Author(s) -
Tong Liu,
Mengdi Xia,
Yongji Zhang,
Yibin Wang,
Yun Zhou
Publication year - 2021
Publication title -
srpski arhiv za celokupno lekarstvo
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.135
H-Index - 17
eISSN - 2406-0895
pISSN - 0370-8179
DOI - 10.2298/sarh200519031l
Subject(s) - medicine , adiponectin , adiponectin receptor 1 , hyperuricemia , gastroenterology , kidney disease , renal injury , endocrinology , kidney , uric acid , obesity , insulin resistance
/Objective. This study aimed to assess the changes of adiponectin (APN), IL-1?, adiponectin receptor 1 (Adipo R1), and NLRP3 expression of patients with idiopathic membranous nephropathy (IMN) complicated with hyperuricemia (HUA) and analyze the relationship between the APN pathway and the NLRP3 pathway. Methods. A group of 48 patients with IMN + HUA, a group of 49 patients with IMN, 30 healthy controls, and 24 samples of healthy renal tissue were evaluated. APN and IL-1? of each group were detected by the ELISA method. AdipoR1 and NLRP3 in kidney tissue were detected by immunohistochemistry. The clinical data of each group were collected, and the relationship between APN, IL-1?, AdipoR1, NLRP3, and other indexes was analyzed. Results. (1) The concentration of UA, APN, IL-1?, and NLRP3 in the IMN + HUA group were significantly higher than those in the IMN group, but the AdipoR1 was lower. (2) With the severity of chronic kidney disease stage, APN, IL-1?, and NLRP3 gradually increased in the IMN + HUA group, but AdipoR1 gradually decreased. However, the aforementioned indicators did not change significantly in the IMN stages. Conclusion. The AdipoR1?AMPK and NLRP3?caspase-1?IL-1? signaling pathway may play an essential role in IMN + HUA patients. An intervention on these two pathways may have significant impact on the disease occurrence and progression in IMN + HUA patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here